Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)   Commentary on Twitter NEW Research—#Benralizumab significantly reduced exacerbation […]

The post Randomized trial: Benralizumab effects on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma appeared first on Links Medicus.